Advanced

Adverse events in apheresis: An update of the WAA registry data.

Mörtzell Henriksson, M; Newman, E; Witt, V; Derfler, K; Leitner, G; Eloot, S; Dhondt, A; Deeren, D; Rock, G and Ptak, J, et al. (2016) In Transfusion and Apheresis Science 54(1). p.2-15
Abstract
Apheresis with different procedures and devices are used for a variety of indications that may have different adverse events (AEs). The aim of this study was to clarify the extent and possible reasons of various side effects based on data from a multinational registry. The WAA-apheresis registry data focus on adverse events in a total of 50846 procedures in 7142 patients (42% women). AEs were graded as mild, moderate (need for medication), severe (interruption due to the AE) or death (due to AE). More AEs occurred during the first procedures versus subsequent (8.4 and 5.5%, respectively). AEs were mild in 2.4% (due to access 54%, device 7%, hypotension 15%, tingling 8%), moderate in 3% (tingling 58%, urticaria 15%, hypotension 10%, nausea... (More)
Apheresis with different procedures and devices are used for a variety of indications that may have different adverse events (AEs). The aim of this study was to clarify the extent and possible reasons of various side effects based on data from a multinational registry. The WAA-apheresis registry data focus on adverse events in a total of 50846 procedures in 7142 patients (42% women). AEs were graded as mild, moderate (need for medication), severe (interruption due to the AE) or death (due to AE). More AEs occurred during the first procedures versus subsequent (8.4 and 5.5%, respectively). AEs were mild in 2.4% (due to access 54%, device 7%, hypotension 15%, tingling 8%), moderate in 3% (tingling 58%, urticaria 15%, hypotension 10%, nausea 3%), and severe in 0.4% of procedures (syncope/hypotension 32%, urticaria 17%, chills/fever 8%, arrhythmia/asystole 4.5%, nausea/vomiting 4%). Hypotension was most common if albumin was used as the replacement fluid, and urticaria when plasma was used. Arrhythmia occurred to similar extents when using plasma or albumin as replacement. In 64% of procedures with bronchospasm, plasma was part of the replacement fluid used. Severe AEs are rare. Although most reactions are mild and moderate, several side effects may be critical for the patient. We present side effects in relation to the procedures and suggest that safety is increased by regular vital sign measurements, cardiac monitoring and by having emergency equipment nearby. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adverse events, Albumin, Apheresis, Donor, Plasma
in
Transfusion and Apheresis Science
volume
54
issue
1
pages
2 - 15
publisher
Elsevier
external identifiers
  • pmid:26776481
  • scopus:84954304755
  • wos:000374614700002
ISSN
1473-0502
DOI
10.1016/j.transci.2016.01.003
language
English
LU publication?
yes
id
fbe5c160-409e-4caf-b214-8c34e5f23409 (old id 8577414)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26776481?dopt=Abstract
date added to LUP
2016-02-16 10:39:33
date last changed
2017-11-19 03:15:54
@article{fbe5c160-409e-4caf-b214-8c34e5f23409,
  abstract     = {Apheresis with different procedures and devices are used for a variety of indications that may have different adverse events (AEs). The aim of this study was to clarify the extent and possible reasons of various side effects based on data from a multinational registry. The WAA-apheresis registry data focus on adverse events in a total of 50846 procedures in 7142 patients (42% women). AEs were graded as mild, moderate (need for medication), severe (interruption due to the AE) or death (due to AE). More AEs occurred during the first procedures versus subsequent (8.4 and 5.5%, respectively). AEs were mild in 2.4% (due to access 54%, device 7%, hypotension 15%, tingling 8%), moderate in 3% (tingling 58%, urticaria 15%, hypotension 10%, nausea 3%), and severe in 0.4% of procedures (syncope/hypotension 32%, urticaria 17%, chills/fever 8%, arrhythmia/asystole 4.5%, nausea/vomiting 4%). Hypotension was most common if albumin was used as the replacement fluid, and urticaria when plasma was used. Arrhythmia occurred to similar extents when using plasma or albumin as replacement. In 64% of procedures with bronchospasm, plasma was part of the replacement fluid used. Severe AEs are rare. Although most reactions are mild and moderate, several side effects may be critical for the patient. We present side effects in relation to the procedures and suggest that safety is increased by regular vital sign measurements, cardiac monitoring and by having emergency equipment nearby.},
  author       = {Mörtzell Henriksson, M and Newman, E and Witt, V and Derfler, K and Leitner, G and Eloot, S and Dhondt, A and Deeren, D and Rock, G and Ptak, J and Blaha, M and Lanska, M and Gasova, Z and Hrdlickova, R and Ramlow, W and Prophet, H and Liumbruno, G and Mori, E and Griskevicius, A and Audzijoniene, J and Vrielink, H and Rombout, S and Aandahl, A and Sikole, A and Tomaz, J and Lalic, K and Mazic, S and Strineholm, V and Brink, B and Berlin, G and Dykes, Josefina and Toss, F and Axelsson, C G and Stegmayr, B and Nilsson, T and Norda, R and Knutson, F and Ramsauer, B and Wahlström, A},
  issn         = {1473-0502},
  keyword      = {Adverse events,Albumin,Apheresis,Donor,Plasma},
  language     = {eng},
  number       = {1},
  pages        = {2--15},
  publisher    = {Elsevier},
  series       = {Transfusion and Apheresis Science},
  title        = {Adverse events in apheresis: An update of the WAA registry data.},
  url          = {http://dx.doi.org/10.1016/j.transci.2016.01.003},
  volume       = {54},
  year         = {2016},
}